CD44 and cancer: These studies have shown that cell subpopulations identified according to CD44 [104] or p75 neutrophin receptor (p75NTR or CD271) [105,106] display properties of cancer stem cells and this conclusion is based on the capacity of these cells to initiate tumor, self-renew, and resist to standard chemotherapy.